Trial reportClinical oral investigations2019
Topical pimecrolimus versus betamethasone for oral lichen planus: a randomized clinical trial.
Trial report in Clinical oral investigations, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 4 syntheses or guidelines pooled it, 32 citations in OpenAlex.
- Comparing the efficacy of topical interventions for pain management in oral lichen planus: a time-stratified bayesian network analysis of randomized controlled trials.BMC oral health · 2025Pooled it
- Oral lichen planus: comparative efficacy and treatment costs-a systematic review.BMC oral health · 2022Pooled it
- Efficacy of topical non-steroidal immunomodulators in the treatment of oral lichen planus: a systematic review and meta-analysis.Clinical oral investigations · 2021Pooled it
- Interventions for treating oral lichen planus: corticosteroid therapies.The Cochrane database of systematic reviews · 2020Pooled it
- Significant efficacy of short-course, low-concentration betamethasone mouthwash therapy for severe erosive oral lichen planus: a randomized controlled trial.Clinical oral investigations · 2023Trial
- Evaluation of muco-adhesive tacrolimus patch on caspase-3 induced apoptosis in oral lichen planus: a randomized clinical trial.BMC oral health · 2023Trial
- Efficacy of platelet-rich fibrin compared with triamcinolone acetonide as injective therapy in the treatment of symptomatic oral lichen planus: a pilot study.Clinical oral investigations · 2021Trial
- Role of Stem Cells and Stem Cell Markers in Oral Potentially Malignant Disorders and Malignant Transformation: A Systematic Review.Stem cells international · 2026Review
- Impact of non-steroidal anti-inflammatory drugs on malignant transformation in oral lichen planus: insights from a real-world cohort study.Frontiers in pharmacology · 2026Article
- Evaluating calcineurin inhibitors as alternatives to steroids in treating Oral Lichen Planus: a systematic review and meta-analysis.Frontiers in oral health · 2026Review
- Triamcinolone acetate and triamcinolone-isotretinoin efficacy in oral lichen planus management: Original clinical study.Bioinformation · 2026Article
- Lichen planus-the role of age and gender in clinical appearance and treatment : A narrative review.Wiener medizinische Wochenschrift (1946) · 2025Review
- Impact of exosomes in oral lichen planus: A review with insights into pathogenesis and biomarkers.Journal of dental sciences · 2024Review
- Review
- Comparative Efficacy and Safety of Interventions for the Treatment of Oral Lichen Planus: A Systematic Review and Network Meta-Analysis.Journal of clinical medicine · 2023Review
- Updates on immunological mechanistic insights and targeting of the oral lichen planus microenvironment.Frontiers in immunology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesOral lichen plans (OLP) is a potentially malignant inflammatory mucocutaneous disease. CD133 is an investigated surface marker for cancer stem-like cells (CSCs) that may be involved in tumor initiation in head and neck carcinomas. We compared short-term clinical effectiveness of topical pimecrolimus as selective inflammatory cytokine release inhibitor with betamethasone cream for erosive/atrophic OLP and investigated the influence of this therapy on CD133 expression. MATERIAL AND
methodsThirty patients were randomly assigned into two equal groups to receive topical pimecrolimus (group I) or betamethasone (group II) four times daily for 4 weeks. A marker lesion in each patient were assessed at baseline using clinical score (CS) and visual analog scale (VAS) then at 1, 2, and 4 weeks and after 4 weeks of treatment-free period. CD133 expression was detected in pre- and post-treatment immunostained sections.
resultsBoth drugs showed a reduction in CS, VAS, and CD133 expressions after treatment termination (p < 0.001). Pimecrolimus-treated lesions showed significant higher 1st week reduction in severity (33.1% (22.2)), pain score (57.53% (14.27)), less recurrence in follow-up period and less CD133 expression by the end of the 1st 4 weeks compared with betamethasone.
conclusionPimecrolimus showed earlier clinical response and less recurrence rate compared with standard topical corticosteroid in symptomatic OLP lesions, and both treatment reduced CD133-positive CSC population. CLINICAL RELEVANCE: The study proved the benefits of topical pimecrolimus in early management of painful lesions of OLP and its ability to inhibit CSCs, suggesting a possible role in reducing risk of malignant transformation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.